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 Gastrointestinal stromal tumours (GIST) are the most common type of primary mesenchymal tumour within the wall of 
the gastrointestinal tract. They are usually derived from a mutation of the KIT or PDGFRA genes. The most common sites 
of GISTs are the stomach and small intestine. Presentation may include local symptoms, such as nausea and vomiting, GI 
bleeding and abdominal pain. Approximately 25% of GISTs are found incidentally during radiological investigations and 
0.7% of resected specimens in bariatric procedures show an incidental GIST. Here we report a case of an incidental micro-
-GIST found on a post-sleeve gastrectomy specimen. 
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Introduction
Hirota et al in 1998 reported the distinction of GISTs based 
on molecular etiology. This was following the discovery of a 
mutation in c-KIT, encoding a pro-oncogenic receptor tyrosine 
kinase (KIT) [1]. GISTs arise in the wall of the gut and account 
for nearly 1% of all GI tumours [2]. They are reported as the 
most common type of primary mesenchymal tumour within 
the digestive tract, with an incidence of 7–20 cases/million 
population/year [3]. They may present with local symptoms, 
or may be diagnosed incidentally during imaging, endoscopy 
or histology.
Case report
A 67-year old female with BMI 45 was referred for elective 
bariatric surgery. Considering several comorbidities (i.e. diabe-
tes, age, hypertension and dyslipidemia), laparoscopic sleeve 
gastrectomy was performed. The patient had a past history 
of lower abdominal surgery with hysterectomy, and radiation 
for moderately differentiated adenocarcinoma of the cervix 
with recurrence. She also had a history of a papillary urothelial 
neoplasm of low malignant potential on the left bladder wall. 
In routine pre-operative practice, ultrasound imaging demon-
strated a normal gallbladder and a normal-sized liver with fatty 
infiltration. Routine gastroscopy and colonoscopy revealed no 
significant findings. Gastric biopsies did not reveal the presence 
of Helicobacter Pylori. On laparoscopic visualization, a cirrhotic 
liver was noted. The lower abdomen had fairly dense-looking 
omental adhesions. No other intra-operative findings were of 
note. The resected specimen consisted of a pouch-like portion 
of stomach, 23 cm (length) × 4.5 cm × 3 cm, closed along one 
long axis with metal staples. The serosal surface was smooth 
and a pale yellow firm nodular area 0.5 cm × 0.2 cm was noted 
within the serosal surface, 0.8 cm from the stapled resection 
margin. The mucosal surface had a normal appearance with 
typical rugae. No masses or polyps were identified. A firm pale 
yellow area was submitted along with representative sections 
from the remainder of the specimen. The microscopic asses-
sment revealed a well-circumscribed lesion showing bland 
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spindle cell proliferation with no atypia, necrosis, or increased 
mitotic rate (Fig. 1, 2). By immunohistochemistry, lesional cells 
were positive for DOG-1 (Fig. 3), c-KIT (Fig. 4) and CD34 (Fig. 5). 
These findings support the final diagnosis of micro-GIST with 
low malignant potential. Four years on from the initial micro-
-GIST diagnosis, there have been no gastrointestinal symptoms 
suggestive of recurrence.
Discussion
GISTs are rare, yet known to be the most common type of 
primary mesenchymal tumour within the wall of the gastroin-
testinal tract. They are primarily caused by activating mutations 
in the KIT gene, which is related to receptor kinase tyrosine 
protein or mutation in platelet derived growth factor receptor 
alpha (PDGFRA) genes [1]. Age at diagnosis ranged from 10 to 
100 years, with a median age of 65, and equal gender distribu-
tion [5]. The most common sites of GISTs are the stomach and 
small intestine [Tab. I], and they are less frequent in the colon 
and oesophagus [4–8]. GISTs are also found to be in extra-vi-
sceral sites, such as omentum, mesentery, pelvis and retroperi-
toneum [7]. The trigger mechanism of pathogenesis is somatic 
gain-of-function mutations in the tyrosine kinase KIT gene 
and thus there is KIT receptor tyrosine kinase activation. This 
Table I . Distribution of GISTs in the gut [4–8]
Stomach Small intestine Colon & rectum Oesophagus
Bethesda 2011 [8] 60% 30% 5% < 1%
Søreide 2014 [5] 56% 32% 6% < 1%
Valsangkar 2015 [4] 60% 35% 5% 1%
Barrios 2015 [8] 60% 30% 5%
Anderson 2016 [6] 77% 15% 8% –
Poveda 2017 [7] 60% 30% 3% 1%
Average 62% 28% 5% 1%
Figure 1 . Low power view showing two micro-GISTs within muscularis 
propria (20×)
Figure 2 . Routine HE staining showing one of the micro-GIST lesions 
(40×)
Figure 3 . Positive immuno-histochemistry with DOG-1 (40×)
Figure 4 . The lesion shows positivity for c-KIT (40×)
Figure 5 . Lesional cells show positive expression for CD34 (40×)
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results in malignant transformation of the interstitial cells of 
Cajal, c-KIT-positive cells of neuroendocrine origin that function 
as the pacemaker in peristalsis, and there is subsequent GIST 
development [9]. Vasilakaki et al suggested that this pathway 
may also be associated with increased cellular proliferation in 
other malignancies, including colorectal adenocarcinoma [10].
There are syndromes known to be associated with GIST; 
there is a common germline mutation which has been de-
tected in a predisposition gene, and is identified as succinate 
dehydrogenase (SDH) deficiency [11–13], KIT or NF1 (Neurofi-
bromatosis Type-1) [14] [Tab. II].
GISTs can present as symptomatic disease or are diagnosed 
incidentally. The common local reported symptoms are nausea 
and vomiting, GI bleeding and abdominal pain. Other findings 
include an abdominal mass, bowel obstruction symptoms and 
peritonitis secondary to perforation [15]. It has been reported 
that about 25% of diagnosed GISTs are found incidentally 
during imaging studies. In one series of autopsy studies, GISTs 
were diagnosed incidentally in 22.5% of cases. The tumours 
can also be detected incidentally during endoscopy [8, 16]. 
In 2018, Yang et al presented a series of 948 patients, who 
underwent bariatric surgery. 0.7% patients were found to 
have incidental gastric GISTs, of which 66.7% males and 33.3% 
females. All of these GISTs were asymptomatic [17].
GISTs may be detected as an isolated pathology or may 
be synchronous with another neoplastic lesion, such as gastric 
adenocarcinoma [18], rectal carcinoma [3], colonic carcinoma 
[9] or neuroendocrine tumour of the pancreas [19]. The co-
-existence of multiple malignancies in the gut from different 
primary origins raises the question of a possible common 
carcinogenesis pathway.
DeMatteo et al in 2000 presented a paper reporting 200 
cases of GIST. About 46% of cases presented as early tumours 
without distant metastasis, 47% had metastases, and only 7% 
presented with isolated local recurrence [20]. Valsangkar et al 
in 2015 also reported that 50% of GIST cases were associated 
with distant metastases at the time of diagnosis. GISTs meta-
stasise through the blood stream or by peritoneal seeding. 
There are some factors which drive or predict its metastasis, 
such as tumour size, frequency of mitoses and presence of 
necrosis [21]. GISTs can also metastasise to remote sites, such 
as liver [22], lung [23], bone [24], ovary [25], brain [26], spleen 
[27] and orbit [28].
The diagnosis, as previously mentioned, can be incidental 
during gastro-intestinal endoscopy or abdominal imaging, 
such as abdominal ultrasound, CT, MRI or PET scan. Tissue 
diagnosis, in addition to immunohistochemistry, is critical in 
working up the GIST diagnosis. This is to differentiate GISTs 
from other intra-abdominal spindle cell neoplasms, such as 
leiomyoma, leiomyosarcoma and schwannoma [29]. 
CD117, or c-KIT, is a receptor tyrosine kinase protein which is 
encoded by KIT gene. It is required for the development and su-
rvival of mast cells, hematopoietic stem cells, melanocytes, germ 
cells and interstitial cells of Cajal. A high specificity and sensitivity 
for this marker has been reported in operated GISTs (up to 97%) 
[3, 30, 31, 32] and c-KIT was positively expressed in our case. 
Discovered on GIST-1 (DOG1), also known as anoctamin 1 
or ANO1, is a chloride channel protein expressed strongly (95%) 
on the cell surface of GISTs and is rarely expressed in other soft 
tissue tumours [29, 33]. In addition, the gene was found to 
encode a calcium-activated chloride channel in the interstitial 
cells of Cajal, which has a critical role in peristalsis, by generating 
slow waves in gastrointestinal smooth muscle [34]. If DOG-1 
expression is negative, this suggests the tumour is not GIST [35]. 
CD34 is an intercellular adhesion protein and cell surface 
glycoprotein. This marker shows expression in early hemato-
poietic and vascular-associated tissue. CD34 antigen expres-
sion has been reported to be positive in more than 91% of 
GISTs [18, 34, 36, 37]. It is also present in Pseudo-Angiomatous 
Stromal Hyperplasia of Breast (PASH) [38] but negative in typical 
leiomyoma [36]. In this case, the cells showed positive stain for 
CD34. Surgical resection of the local disease, including laparo-
scopic approach, is the standard management option [3, 4, 37]. 
Imatinib, a tyrosine kinase inhibitor, was found to be active 
against the Bcr-Abl kinase responsible for the pathogenesis of 
chronic myeloid leukemia (CML). The similarities between KIT 
and Bcr-Abl signalling triggered a clinical trial using Imatinib 
in patients with metastatic GIST, and resulted in clinically re-
levant responses [39]. With new developments in molecular 
diagnosis and the introduction of tyrosine kinase inhibitors 
(TKIs) as neoadjuvant treatment prior to GIST surgery, patient 
outcomes have improved markedly [4].
Conclusions
Incidental finding of GISTs after laparoscopic bariatric sur-
gery is rare, yet still a possibility. Radical surgical resection of 
Table II . Syndromes known to be associated with GIST [11–14]
Mutation Syndrome Syndrome elements
SDH-deficiency Carney Triad [11] GIST
Paraganglioma
Pulmonary chondroma
Carney-Stratakis Syndrome [12, 13] GIST
Paraganglioma
Inactivating mutations in NF1 gene NF1 [14] A wild-type small intestinal GIST
Neurofibromatosis
SDH – succinate dehydrogenase, NF1 – neurofibromatosis type-1
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GISTs is recommended to achieve effective treatment witho-
ut complications or disease recurrence.A follow-up program 
according to the agreed guidelines in case of GIST diagnosed 
after bariatric surgery is advisable to allowearly detection and 
treatment of relapses.
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